{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:45:29Z","timestamp":1788014729421,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-026-00859-1","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:50:42Z","timestamp":1774626642000},"page":"323-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintaining complete response to avelumab for lung metastases from native ureteral cancer after kidney transplantation: a case report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1947-5227","authenticated-orcid":false,"given":"Yutaka","family":"Shiono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Koguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyasu","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"859_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s11255-011-9907-z","volume":"43","author":"J Cox","year":"2011","unstructured":"Cox J, Colli JL (2011) Urothelial cancers after renal transplantation. Int Urol Nephrol 43:681\u2013686. https:\/\/doi.org\/10.1007\/s11255-011-9907-z","journal-title":"Int Urol Nephrol"},{"key":"859_CR2","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/ajt.15495","volume":"19","author":"EA Engels","year":"2019","unstructured":"Engels EA (2019) Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. Am J Transplant 19:3223\u20133232. https:\/\/doi.org\/10.1111\/ajt.15495","journal-title":"Am J Transplant"},{"key":"859_CR3","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","volume":"82","author":"J Fisher","year":"2020","unstructured":"Fisher J, Zeitouni N, Fan W, Samie FH (2020) Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol 82:1490\u20131450. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.005","journal-title":"J Am Acad Dermatol"},{"key":"859_CR4","doi-asserted-by":"publisher","unstructured":"Aguirre LE, Guzman ME, Lopes G, Hurley J (2019) Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 24:394\u2013401. https:\/\/doi.org\/10.1634\/theoncologist.2018\u2009\u2212\u20090195","DOI":"10.1634\/theoncologist.2018\u2009\u2212\u20090195"},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/nejmoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218\u20131230. https:\/\/doi.org\/10.1056\/nejmoa2002788","journal-title":"N Engl J Med"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/nejmoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/nejmoa1613683","journal-title":"N Engl J Med"},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/iju5.12438","volume":"5","author":"J Kamei","year":"2022","unstructured":"Kamei J, Yokoyama H, Niki T et al (2022) Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney. IJU Case Reports 5:199\u2013202. https:\/\/doi.org\/10.1002\/iju5.12438","journal-title":"IJU Case Reports"},{"key":"859_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","volume":"100","author":"N Murakami","year":"2021","unstructured":"Murakami N, Mulvaney P, Danesh M et al (2021) A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 100:196\u2013205. https:\/\/doi.org\/10.1016\/j.kint.2020.12.015","journal-title":"Kidney Int"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2021.01.038","volume":"148","author":"LS Nguyen","year":"2021","unstructured":"Nguyen LS, Ortuno S, Lebrun-Vignes B et al (2021) Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur J Cancer 148:36\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.038","journal-title":"Eur J Cancer"},{"key":"859_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","volume":"351","author":"J Dantal","year":"1998","unstructured":"Dantal J, Hourmant M, Cantarovich D et al (1998) Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351:623\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(97)08496-1","journal-title":"Lancet"},{"key":"859_CR11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.transproceed.2015.12.071","volume":"48","author":"YJ Wang","year":"2016","unstructured":"Wang YJ, Chi NH, Chou NK et al (2016) Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression. Transplant Proc 48:969\u2013973. https:\/\/doi.org\/10.1016\/j.transproceed.2015.12.071","journal-title":"Transplant Proc"},{"key":"859_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010249","volume":"11","author":"R Imamura","year":"2022","unstructured":"Imamura R, Tanaka R, Taniguchi A et al (2022) Everolimus reduces cancer incidence and improves patient and graft survival rates after kidney transplantation: a multi-center study. J Clin Med 11:249. https:\/\/doi.org\/10.3390\/jcm11010249","journal-title":"J Clin Med"},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4240\/wjgs.v13.i10.1267","volume":"13","author":"KP Au","year":"2021","unstructured":"Au KP, Chok KSH (2021) Immunotherapy after liver transplantation: where are we now? World J Gastrointest Surg 13:1267\u20131278. https:\/\/doi.org\/10.4240\/wjgs.v13.i10.1267","journal-title":"World J Gastrointest Surg"},{"key":"859_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","volume":"20","author":"AJ Portuguese","year":"2022","unstructured":"Portuguese AJ, Tykodi SS, Blosser CD, Gooley TA, Thompson JA, Hall ET (2022) Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review. J Natl Compr Canc Netw 20:406-416.e11. https:\/\/doi.org\/10.6004\/jnccn.2022.7009","journal-title":"J Natl Compr Canc Netw"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-026-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-026-00859-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-026-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:39:51Z","timestamp":1784180391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-026-00859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s13691-026-00859-1","relation":{},"ISSN":["2192-3183"],"issn-type":[{"value":"2192-3183","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to our Institutional Review Board, ethics approval is not required for case reports, so this case report also did not require ethics approval. Informed consent by verbal consent was obtained from the patient for the publication of this case report and accompanying images.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to our Institutional Review Board, ethics approval is not required for case reports, so this case report also did not require ethics approval. Informed consent by verbal consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to our Institutional Review Board, ethics approval is not required for case reports, so this case report also did not require ethics approval. Informed consent by verbal consent was obtained from the patient for the publication of this case report and accompanying images.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}